论文部分内容阅读
目的 :观察 L atanoprost的降眼压效果及安全性。方法 :采用随机分组对照法 ,0 .0 0 5 % L atanoprost每日一次或 0 .5 % Timolol(噻吗心安 )每日 2次 ,治疗原发性开角型青光眼、高眼压症和剥脱性青光眼 ,共 14例 ,疗程 12周 ,观察其眼压及不良反应。结果 :L atanoprost组和 Timolol组均可有效地降低眼压 (P<0 .0 1) ,两组间眼压下降值没有差异。两组治疗前后不同时间点眼压下降值没有波动。有 2例用 L atanoprost患者出现结膜充血 ,未发现其他眼部改变和全身副作用。结论 :研究表明 L atanoprost是一种稳定、有效的降眼压药物 ;眼局部反应轻微 ,没有全身副作用。 L atanoprost可望成为一种安全、理想的第一线抗青光眼药物
Objective: To observe the hypotensive effect and safety of L atanoprost. Methods: A randomized controlled trial of 0. 05% L atanoprost once daily or 0.5% Timolol twice daily for the treatment of primary open-angle glaucoma, ocular hypertension and exfoliation A total of 14 cases of glaucoma, treatment for 12 weeks, observe the intraocular pressure and adverse reactions. RESULTS: The LOPP group and Timolol group both reduced intraocular pressure (P <0. 01), and there was no difference in IOP between the two groups. IOP values at two different time points before and after treatment did not fluctuate. Conjunctival hyperemia occurred in 2 patients with L atanoprost and no other ocular changes and systemic side effects were observed. CONCLUSIONS: L-antanoprost is a stable and effective antihypertensive drug; eye local reactions are mild with no systemic side effects. L atanoprost is expected to be a safe, ideal first-line anti-glaucoma medication